IgD multiple myeloma - retrospective analysis of therapeutic results of 4 centres of the Czech Republic over the last 7 years
2007
Abstract
IgD multiple myeloma belongs to relatively rare types of plasmacytomas and affects less than 2% of all MM-patients. Survival of patients with IgD MM is generally believed to be shorter than that of patients with other types of M-protein.
We carried out a retrospective analysis of 20 myeloma patients treated by 4 Czech hemato-oncological centers in last seven years. It is necessary to consider high-dose therapy with following APBSCT when treating patients with IgD MM under 65 years because it is possible to reach similar results compared to patients with other MM types.